This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

H.C. Wainwright Keeps Their Buy Rating on Cardiol Therapeutics (CRDL)

Tipranks - Tipranks - Wed May 27, 1:00PM CDT

In a report released today, Brandon Folkes from H.C. Wainwright maintained a Buy rating on Cardiol Therapeutics, with a price target of $9.00.

Memorial Day Sale – Claim 70% Off TipRanks

According to TipRanks, Folkes is an analyst with an average return of -0.9% and a 37.80% success rate. Folkes covers the Healthcare sector, focusing on stocks such as Heron Therapeutics, Achieve Life Sciences, and Collegium Pharmaceutical.

In a report released on May 19, Canaccord Genuity also reiterated a Buy rating on the stock with a $8.00 price target.

See today’s best-performing stocks on TipRanks >>

Based on Cardiol Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of C$10.82 million. In comparison, last year the company had a GAAP net loss of C$8.29 million

Read More on CRDL:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).